I Chair the Alberta Pre-Phase 1 Cancer Program that brings Alberta-made anticancer compounds to first-in-human testing, and work with academic collaborators to bring their ideas to the clinic. My translational research program focuses on developing tests to predict which patients are most likely to benefit from anticancer therapy, and exploiting novel targets and pathways to improve systemic cancer therapy. My research program is funded by the Alberta Cancer Foundation, the Canadian Breast Cancer Research Alliance, the US Department of Defense, and multiple industry sponsors.